AH
APLS

Andreas Halvorsen’s Apellis Pharmaceuticals APLS Stock Holding History

Andreas Halvorsen’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-932,441
Closed -$63.7M – 77
2022
Q3 		$63.7M Buy
+932,441
New +$55.2M 0.29% 65

Other funds holding APLS

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Andreas Halvorsen's APLS Position: Q4 2022 in Review

Andreas Halvorsen sold out of Apellis Pharmaceuticals (APLS) in Q4 2022, closing a stake of 932,441 shares — an estimated $63.7M sold.

Andreas Halvorsen first reported a position in APLS in Q3 2022 and held it in 1 quarter. The position peaked at $63.7M in Q3 2022. 244 funds tracked by Wall St. Rank hold APLS as of Q4 2022.

  • Andreas Halvorsen reported no remaining Apellis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Andreas Halvorsen sold 932,441 Apellis Pharmaceuticals shares in Q4 2022, an estimated $63.7M.
  • Andreas Halvorsen first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Andreas Halvorsen's Apellis Pharmaceuticals position peaked at $63.7M in Q3 2022.
  • 244 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2022.

Based on Viking Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.